The FDA approved Watson Pharmaceuticals' Gelnique to treat an overactive bladder. The gel is intended to avert adverse reactions linked to other versions of oxybutynin, the product's active ingredient. The company expects to launch Gelnique as a prescription medication in the second quarter of this year.

Full Story:

Related Summaries